Welcome to our dedicated page for Semnur Pharmaceuticals SEC filings (Ticker: SMNR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Semnur Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Semnur Pharmaceuticals's regulatory disclosures and financial reporting.
Semnur Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company developing non-opioid pain treatments, led by SP-102, a viscous dexamethasone gel for epidural injection in sciatica. A pivotal Phase 3 CLEAR-1 trial in 401 patients met its primary and most secondary endpoints, showing statistically significant and clinically meaningful pain and disability improvements versus placebo with a favorable safety profile.
The company began its second Phase 3 CLEAR-2 trial in September 2025, targeting about 700 patients and aiming for a 505(b)(2) NDA filing by 2027 and a potential U.S. launch in 2028, if approved. Semnur operates as a reverse‑recapitalized successor to Denali Capital Acquisition Corp., leverages Scilex’s commercial infrastructure, and highlights a large U.S. epidural steroid injection market, where independent research projects potential SP-102 peak annual sales of $1.5–$2.0 billion by year five post‑launch.
Semnur Pharmaceuticals, Inc. has filed an amended registration statement covering the resale of up to 203,737,349 shares of common stock, the issuance of up to 8,760,000 shares upon exercise of warrants, and the resale of up to 510,000 private warrants. The company will receive cash only if holders exercise the 8,250,000 public warrants and 510,000 private placement warrants, while selling securityholders receive any proceeds from share and warrant resales.
Semnur is a late-stage clinical biopharmaceutical company developing non-opioid pain therapies. Its lead Phase 3 candidate, SP-102 (SEMDEXA), is a dexamethasone sodium phosphate viscous gel being developed as a preservative-free, pre-filled syringe epidural steroid injection for lumbosacral radicular pain (sciatica) and has FDA fast track designation. In 2025 Semnur completed a SPAC business combination with Denali Capital Acquisition Corp., redomiciling from the Cayman Islands to Delaware and becoming a Scilex-controlled subsidiary.
The prospectus highlights substantial operating and financial risk. Semnur has a single product candidate, has never generated product revenue, reported net losses of $154.3 million for the nine months ended September 30, 2025 and an accumulated deficit of $269.6 million, holds only $0.1 million of cash, faces going concern uncertainty, relies on key third-party manufacturing and supply relationships, and has identified material weaknesses in internal controls.
Semnur Pharmaceuticals, Inc. filed a current report to update the official description of its securities. The company’s common stock trades under the symbol SMNR, and its warrants to purchase common stock at an exercise price of $11.50 per share trade under the symbol SMNRW. The updated description reflects amendments to Semnur’s Certificate of Incorporation and Bylaws made since the end of its fiscal year ended December 31, 2024.
The revised Description of Securities is provided as Exhibit 4.1 and replaces any earlier descriptions contained in prior registration statements or reports. It may be incorporated by reference into future Semnur filings under the Securities Act of 1933 and the Securities Exchange Act of 1934, helping keep investors and regulators aligned on the current rights and terms associated with the company’s equity and warrants.
Semnur Pharmaceuticals (SMNR) filed its Q3 10‑Q, reporting a net loss of
Management disclosed that these conditions raise substantial doubt about the company’s ability to continue as a going concern. Following the September 22, 2025 business combination and reverse recapitalization, 229,740,978 common shares were outstanding as of November 10, 2025. At closing, the company issued 26.5M shares to consultants and 100K shares to underwriters; related-party debt of
Two financing agreements were signed but had not closed by September 30, 2025: a PIPE for 1,250,000 shares at
Semnur Pharmaceuticals, Inc. filed a Form S-1 registering the resale of up to 203,737,349 shares of common stock and the issuance of up to 8,760,000 shares upon exercise of warrants, plus 510,000 private warrants. The resale pool includes 188,554,849 Scilex Shares, 2,072,500 Sponsor Shares, 100,000 Underwriter Shares, 12,500,000 Biconomy Resale Shares, and 510,000 Private Warrant Shares.
The company will receive cash only if holders exercise the 8,250,000 Public Warrants and 510,000 Private Warrants; it will not receive proceeds from Selling Securityholders’ resales. This filing follows the September 22, 2025 business combination and domestication with Denali Capital Acquisition Corp., after which the company was renamed Semnur.
Common stock and public warrants trade on OTC Pink as SMNR and SMNRW; on October 17, 2025, last reported prices were $9.00 per share and $0.20 per warrant. Semnur is an emerging growth company developing SP-102 for sciatica and discloses going concern risks and previously identified material weaknesses in internal control.